Fase III Actualizada A Randomized, Multicenter .Yondelis Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With TRS .

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PharmaMar
Investigators
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.




Administrative Data
Organization name Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization study ID CR015769
Secondary ID ET-C-002-07
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborator PharmaMar
Health Authority United States: Food and Drug Administration